According to Chiesi Group, a Phase 1 trial of its inhaled phosphodiesterase 4 (PDE4) inhibitor for the treatment of lung diseases such as COPD and asthma demonstrated that the drug, known as CHF 6001, was well tolerated in healthy volunteers at doses of up to 2000 µg for up to 7 days. In vitro and animal studies have shown that CHF 6001 is more potent than roflumilast, an oral PDE4 inhibitor marketed as Daxas and Daliresp, the company says.
Chiesi also says that two Phase 2a proof of concept studies of CHF 6001 in patients with asthma and COPD are underway based on the Phase 1 results.
Read the Chiesi press release.
